Altesa Biosciences develops drugs to treat RNA viruses, which are responsible for 80% of viral diseases worldwide. Among these viruses are Rhinovirus (primary cause of the common cold), Influenza, Respiratory Syncytial Virus (RSV), Dengue virus, Yellow Fever virus, Ebola virus and SARS-CoV-2 (COVID-19).
Altesa Biosciences website »
Location: United States
Investors 1
| Date | Name | Website |
| - | GRA Ventur... | graventure... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 10.05.2023 | NCPDP Announces Highlights from its 2023 Annual Conference, ... | National Council for Prescription Drug Programs (NCPDP) SCOTTSDALE, Ariz. (PRWEB) May 10, 2023 NCP... | prweb.com/... |
| 07.07.2021 | Vaxart : Announces Exclusive Worldwide License Agreement wit... | Milestone payments up to $130 million and royalties for global Vapendavir sales Vapendavir has demo... | marketscre... |
| - | Altesa | “Altesa BioSciences | Developing Treatments For Respiratory Viruses and Global Viral Threats” | fastfounde... |